Diagam SA
23.9 FTEDiagam reported total assets of €7.25m at the end of the 2025 financial year (annual accounts filed with the NBB on 30 Sep 2026), with 23.9 full-time equivalents.
The score of Diagam shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +42 % Total assets +56 % Headcount (avg FTE) +32 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Diagam's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 30 Sep 2026
- Year ended 31 Dec 2024filed on 29 Aug 2025
- Year ended 31 Dec 2023filed on 29 Aug 2024
- Year ended 31 Dec 2022filed on 10 Oct 2023
- Year ended 31 Dec 2021filed on 31 Aug 2022
Diagam's financial analysis
- Solvency55.2%sector median: 38.7%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Diagam
Diagam's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0451.236.575
- VAT number
- BE0451236575
- Peppol
- Registered · 0208:0451236575 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 26 Oct 1993
- Registered office
- 7822 Ath
- Size
- Small · 23.9 FTE
- Latest accounts
- 2025 · filed on 30 Sep 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
Diagam (SA) has been based in Ath since 1993, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net profit of €1.28m and equity of €4.00m; its revenue is not published. With 23.9 full-time equivalents, it is a small enterprise by headcount. Its solvency stands at 55.2%, above the median of its sector (38.7%).
Companies similar to Diagam
Companies in the same business, of comparable size and area, outside its group.
- Alexion Pharma Belgium Manufacture of pharmaceutical preparations Brussels · balance sheet €8.68m
- Surveal Pharma Wholesale of pharmaceutical and medical goods Ixelles · balance sheet €5.47m
- L - Pharma Manufacture of pharmaceutical preparations Turnhout · balance sheet 10 €
- RTLC Manufacture of pharmaceutical preparations Brussels · balance sheet 107,167 €
- Dermax Wholesale of pharmaceutical and medical goods Liège · balance sheet €5.73m
- AnalytiChem Belgium Manufacture of other inorganic basic chemicals Zedelgem · balance sheet €13.5m
- BePharBel Manufacturing Manufacture of basic pharmaceutical products Courcelles · balance sheet €27.4m
- Magis-Pharma Wholesale of pharmaceutical and medical goods Antwerp · balance sheet €12.5m
Frequently asked questions about Diagam
What is the revenue of Diagam?
Diagam files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Diagam?
In Belgium, the VAT number is the company number prefixed with BE: BE0451236575 for Diagam, if the company is VAT-registered. Its company number (CBE) is 0451.236.575.
Where is the registered office of Diagam?
According to the CBE register, the registered office of Diagam is in 7822 Ath.
What is the equity of Diagam?
At the close of the 2025 financial year, the equity of Diagam amounts to 4,002,670 €, a solvency of 55.2% of total assets.
How many people work at Diagam?
23.9 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Diagam?
The register lists 7 active mandates at Diagam. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Diagam
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →